1. Volume 57, Issue 1, Pages 25-31 (January 2010)
Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study 
Miloš Duchek, Robert Johansson, Staffan Jahnson, Oddvar Mestad, Pekka Hellström, Sverker Hellsten, Per-Uno Malmström 
European Urology 
Volume 57, Issue 1, Pages (January 2010)
DOI: /j.eururo
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1 Treatment and assessment schedule.
TURB=Transurethral resection of the bladder*; R=randomisation; Pex=multiple biopsies; BCG=bacillus Calmette-Guérin; IFN=interferon-α2b; Epi=epirubicin.
* If no tumour, TURB at primary location; second look refers to TURB at the primary tumour location plus mapping.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Flow of patients.
BCG=bacillus Calmette-Guérin; Epi=epirubicin; IFN=interferon-α2b.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Disease-free survival of patients according to randomisation arm (p=0.01).
DFS=disease-free survival; BCG=bacillus Calmette-Guérin.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

5. Fig. 4
Progression-free survival of patients according to randomisation arm.
DFS=disease-free survival; BCG=bacillus Calmette-Guérin.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

6. Fig. 5
Disease-free survival in subgroups according to (a) Tis (p<0.001), (b) grade 2 (p=0.09), and (c) grade 3 (p=0.055) status.
DFS=disease-free survival; BCG=bacillus Calmette-Guérin; CIS=carcinoma in situ; Epi=epirubicin; IFN=interferon-α2b.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

7. Fig. 6
Frequency of patients (%) with subjective urinary problems during treatment months.
BCG=bacillus Calmette-Guérin; Epi=epirubicin; IFN=interferon-α2b.
European Urology  , 25-31DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions